Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | ODESSY: real world outcomes on active surveillance in mRCC

Michael Harrison • 31 May 2025
ASCO 2025
Genitourinary Cancer Kidney Cancer
ODYSSEY

Michael Harrison, MD, Duke University School of Medicine, Durham, NC, discusses the ODYSSEY study (NCT04919122), a prospective observational trial evaluating quality of life in patients (QoL) with metastatic renal cell carcinoma (mRCC) on active surveillance versus systemic therapy. Patients on active surveillance showed better baseline quality of life compared to those on systemic therapy and similar outcomes to those reported in prior randomized trials. These findings highlight the potential role of active surveillance in select patients to preserve quality of life while deferring treatment-related toxicity. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Harrison

Using early QoL data to identify patients with high-risk RCC
0:55
Using early QoL data to identify patients with high-risk RCC
Michael Harrison • 26 Feb 2026
ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC
2:30
ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC
Michael Harrison • 26 Feb 2026
The role of active surveillance for patients with metastatic kidney cancer
1:24
The role of active surveillance for patients with metastatic kidney cancer
Michael Harrison • 31 May 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals